• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Hematology

Latest News

Doctor results older woman | Image credit: Felix/peopleimages.com - stock.adobe.com
Challenging Fixed Age Cut-Offs for AML Treatment, Clinical Trials

November 17th 2025

Research challenges age cut-offs in AML treatment, advocating for flexible, individualized approaches based on continuous age assessment.

FDA approval | Image Credit: © muh-stock.adobe.com
FDA Approves Daratumumab and Hyaluronidase-fihj for High-Risk MM

November 6th 2025

Defining the Comprehensive Role of the Oncology Pharmacist in Multiple Myeloma: Marcus Flores, PharmD, BCPS, BCOP
Defining the Comprehensive Role of the Oncology Pharmacist in Multiple Myeloma: Marcus Flores, PharmD, BCPS, BCOP

October 31st 2025

The authors emphasized the importance of multidisciplinary care at diagnosis, especially in elderly patients or those with CV disease, even if asymptomatic, to optimize outcomes and minimize treatment discontinuation. | Image credit: sovova - stock.adobe.com
Balancing Efficacy and Safety in BTKi Therapy

October 31st 2025

CAR T-cell therapy | Image Credit: Funny -stock.adobe.com
Real-World Data Key to Optimizing CAR T-Cell Therapy Delivery, Outcomes

October 29th 2025

More News

Extending Anticoagulation With Apixaban Reduces Recurrent VTE

Extending Anticoagulation With Apixaban Reduces Recurrent VTE

Henri Stanton
December 9th 2012

Extended anticoagulation with fixed doses of the oral Factor Xa inhibitor apixaban significantly reduced the incidence of symptomatic recurrent venous thromboembolism (VTE) or death without increasing the risk of major bleeding in patients with VTE who had already completed up to 12 months of anticoagulation.

Read More

<1
...
2627282930
© 2025 MJH Life Sciences
AJMC®
All rights reserved.